On Nov. 16, 2021, Illumina and Genetic Alliance announced the creation of the iHope Genetic Health program aimed at providing whole-genome sequencing access (WGS) to tens of thousands of patients across the globe impacted by genetic disease. At least half of iHope Genetic Health’s efforts were focused on areas of the world in need outside the US, with more than one-third of Illumina’s support being dedicated to patients in Africa.

Through this flagship program, Illumina will enable Genetic Alliance, a global nonprofit focused on advancing genetics to benefit human health, to create networks of clinics, and laboratories equipped with the necessary genome technology to provide precision genomic diagnoses to patients suffering from rare genetic disease. As part of this program, Genetic Alliance will also partner with pharmaceutical, technology companies and care providers to support patient access to data, therapeutic interventions, and ongoing supportive care.

iHope Genetic Health will build upon the success of Illumina’s existing iHope efforts, further extending the reach of the program and enabling clinical laboratories and care centers throughout the world to test patients impacted by rare disease and other genetic health conditions. Genetic disease affects over 300 million individuals worldwide, the vast majority of whom are children. In high income countries these patients often remain undiagnosed for up to seven years, while in low- and middle-income geographies, many families never know the cause of their child’s suffering. Further enabling access will help reduce the psychological stress and loss of income that many families endure.